BidaskClub upgraded shares of Integra Lifesciences (NASDAQ:IART) from a hold rating to a buy rating in a report published on Friday.
IART has been the subject of several other research reports. Oppenheimer reissued a buy rating on shares of Integra Lifesciences in a research report on Thursday, January 11th. Barclays reissued a hold rating and issued a $53.00 target price on shares of Integra Lifesciences in a research report on Tuesday, January 9th. Jefferies Group reissued a buy rating and issued a $63.00 target price on shares of Integra Lifesciences in a research report on Thursday, March 1st. UBS lowered Integra Lifesciences to a market perform rating in a research report on Tuesday, January 2nd. Finally, Raymond James Financial reissued a market perform rating and issued a $55.00 target price on shares of Integra Lifesciences in a research report on Tuesday, January 2nd. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $54.90.
Integra Lifesciences (NASDAQ:IART) traded down $1.60 on Friday, reaching $54.15. The company’s stock had a trading volume of 505,529 shares, compared to its average volume of 561,205. The company has a market cap of $4,376.05, a price-to-earnings ratio of 66.04, a price-to-earnings-growth ratio of 1.72 and a beta of 0.65. The company has a debt-to-equity ratio of 1.85, a current ratio of 2.36 and a quick ratio of 1.51. Integra Lifesciences has a fifty-two week low of $40.51 and a fifty-two week high of $58.17.
In related news, VP Joseph Vinhais sold 6,800 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $54.13, for a total transaction of $368,084.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Glenn Coleman sold 8,769 shares of the firm’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $56.10, for a total value of $491,940.90. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,765 shares of company stock valued at $4,314,208. 21.50% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its position in Integra Lifesciences by 3.4% during the 4th quarter. BlackRock Inc. now owns 8,135,552 shares of the life sciences company’s stock valued at $389,367,000 after buying an additional 269,484 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in Integra Lifesciences by 2.4% during the 4th quarter. Champlain Investment Partners LLC now owns 4,646,075 shares of the life sciences company’s stock valued at $222,361,000 after purchasing an additional 110,355 shares during the last quarter. Clearbridge Investments LLC boosted its stake in Integra Lifesciences by 0.3% during the 4th quarter. Clearbridge Investments LLC now owns 1,294,287 shares of the life sciences company’s stock valued at $61,945,000 after purchasing an additional 3,561 shares during the last quarter. Orbimed Advisors LLC boosted its stake in Integra Lifesciences by 155.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after purchasing an additional 664,000 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Integra Lifesciences by 7.8% during the 4th quarter. Wells Fargo & Company MN now owns 869,537 shares of the life sciences company’s stock valued at $41,616,000 after purchasing an additional 63,204 shares during the last quarter. 90.92% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3296283/integra-lifesciences-iart-rating-increased-to-buy-at-bidaskclub.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.